While oncology drug development continues to be fairly lively, a drop in FDA applications and approvals in other therapeutic areas may raise concerns about the longer-term outlook for treatment options.
Reviewing data on applications received and approved by the Center for Drug Evaluation and Research since 2013, Office of New Drugs Director John Jenkins pointed out, "There's a fairly substantial decline in the number of non-oncology NMEs approved compared to last year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?